1. Pink Sheet

“We Regulators Need To Get Our Heads Round Big Data”: EU Task Force Chair

 
• By Vibha Sharma

The EU big data task force seems to be on track to deliver in 2018 an EU-wide strategy on how big data can be used to support the development and evaluation of medicines. Some aspects of big data, such as social media and mobile health, have proved to be more challenging than others, says task force co-chair Thomas Senderovitz.

Businessman searching for big data
EU Regulatory Group Is Working To Deliver A Big Data Strategy In 2018 • Source: Shutterstock

The EU task force mandated with exploring opportunities and challenges associated with the use of big data in regulatory decision-making has launched two surveys – one for pharmaceutical companies and the other for national competent authorities - to ascertain the current landscape on how big data is being used across the drug development pathway.

The task force, which was jointly formed by the European Medicines Agency and the EU Heads of Medicines Agencies in March this year, appears to have made good progress over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

MAHA Commission Outlines Enhanced Research On Drug Safety In Children

 
• By Cathy Kelly

Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.